Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
J Ints Bio (South Korea)
Homepage:
jintsbio.com
Alternate name:
J Ints Bio
ROR:
02r3j9j80
OpenAlex ID:
I4405263113
Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility
2022
·
Han-Sol Kim
, Chang-Min Kim
, et al.
·
Pharmaceuticals
·
18
PDF
Exploratory investigation of the correlation between microplastics and breast cancer: Polystyrene-derived microplastics promote cell proliferation via estrogenic endocrine disruption
2025
·
Seoung-Woo Lee
, Hee-Yeon Kim
, et al.
·
Journal of environmental chemical engineering
·
17
Protein Microplastic Coronation Complexes Trigger Proteome Changes in Brain-Derived Neuronal and Glial Cells
2025
·
Janbolat Ashim
, Sangho Ji
, et al.
·
Environmental Science & Technology
·
10
999P JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC
2022
·
M.R. Yun
, M.R. Yu
, et al.
·
Annals of Oncology
·
10
MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC
2022
·
M.R. Yun
, M.R. Yu
, et al.
·
Journal of Thoracic Oncology
·
10
Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC).
2024
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Journal of Clinical Oncology
·
7
PDF
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC
2026
·
Eun Ji Lee
, Ji Ae Ko
, et al.
·
Clinical Cancer Research
·
6
PDF
Tracking temporal progression of benign bone tumors through X-ray based detection and segmentation
2025
·
Se-Yeol Rhyou
, Chohee Bang
, et al.
·
Scientific Reports
·
5
PDF
PRPF4 Knockdown Suppresses Glioblastoma Progressionviathe p38 MAPK and ERK Signaling Pathways
2025
·
WANSOO KIM
, SONG PARK
, et al.
·
Anticancer Research
·
3
P3.12D.02 Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutated Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)
2024
·
S.M. Lim
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
hMAGEA2Accelerates the Progression of Prostate Cancerviathe EFNA3–Erk1/2 Signaling Pathway
2024
·
SEHYEON HAN
, SOYOUNG JANG
, et al.
·
Anticancer Research
·
3
Veratramine Inhibits Human Non-Small Cell Lung Cancer Cell Growth by Inhibiting the Hedgehog Signaling Pathway
2025
·
Seoung-Woo Lee
, Hee-Yeon Kim
, et al.
·
Journal of pharmacopuncture
·
2
Dddr-30. Enhanced Chemo and Radio-sensitization of Gliomas by Hsp90 Inhibition With Jin-001, a Novel Blood-brain Barrier Penetrant Hsp90 Inhibitor
2024
·
Jihong Xu
, Harsha S Sugur
, et al.
·
Neuro-Oncology
·
2
PDF
Abstract CT184: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR mutated advanced/metastatic non-small cell lung cancer
2025
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Cancer Research
·
1
Abstract CT154: Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
2024
·
Sun Min Lim
, Byoung Chul Cho
, et al.
·
Cancer Research
·
1
597TiP A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
2023
·
S.M. Lim
, B.C. Cho
, et al.
·
Annals of Oncology
·
1
PDF
P2.09-09 A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC
2023
·
S.M. Lim
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Abstract 4029: JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC
2023
·
Mi Ra Yu
, Mi Ran Yun
, et al.
·
Cancer Research
·
1
EXTH-35 Role of HSP90 inhibition in modulating the glioblastoma tumor microenvironment
2026
·
Harsha Sugur
, Pratibha Sharma
, et al.
·
Neuro-Oncology
P3.262: Discovery of Drug-Response Biomarkers Using Label-Free Plasma Proteomics in NSCLC Patients Treated With JIN-A02, a Fourth-Generation EGFR-TKI
2026
·
H.-Y. Kim
, S.M. Lim
, et al.
·
Journal of Thoracic Oncology
Computational prescreening of anticancer drugs prior to in vitro validation, primarily in dogs with exploratory cat data, based on cross-species binding conservation
2026
·
Seoung-Woo LEE
, Hee-Yeon KIM
, et al.
·
Journal of Veterinary Medical Science
PDF
AI-driven virtual transcriptome screening to identify repurposable combination partners for JIN-A02 in NSCLC.
2026
·
Sangyeol Kim
, Anna Jo
, et al.
·
Journal of Clinical Oncology
Dietary sodium intake and prediabetes in Korean adults: a nationally representative cross-sectional analysis of 57,165 participants (KNHANES 2010–2018)
2026
·
Hae Don Kim
, Cheol Won Choi
, et al.
·
Hellenic Journal of Cardiology
P3.18.57 Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
2025
·
S-M. Lim
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
PT2.12.02 Effect of JIN-A02, a Novel 4Th-Generation EGFR-TKI, on Multiple EGFR Mutations in Comparison With 3Rd-Generation EGFR-TKIs
2025
·
S-M. Lim
, B.S. Kim
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
29
Citation count:
293
Year
Topic
Type